The Role of Testing Data in Patent Applications

Summary

Testing data can help establish an invention’s utility and support a claimed therapeutic or functional use.
Working examples can support broader genus claims, particularly when the tested embodiments are representative of the claimed scope.
Testing can help establish a structure-function relationship and support claims to particular properties or results.
Comparative testing can demonstrate unexpected or superior results that may help overcome an obviousness rejection.
The type and amount of testing needed depends on the invention, predictability of the technology, and scope of the claims.

Introduction

Testing data can be an important part of a patent application, particularly for inventions in biotechnology, pharmaceuticals, chemistry, and other fields where the relationship between a structure and its function may not be predictable.

However, patent law does not generally require an inventor to fully test an invention before filing a patent application. The importance of testing data depends on what the inventor is trying to establish and the scope of the claims.

Testing data can help establish that an invention has a useful purpose, support the claimed utility of an invention, demonstrate that representative embodiments of a broader genus work, and provide evidence of unexpected results that may help overcome an obviousness rejection.

Establishing Utility

Every invention claimed in a utility patent must have a specific and substantial utility. In many cases, the intended use of an invention is apparent from the invention itself and does not require extensive testing.

Testing can become more important when the claimed utility depends on a particular biological, chemical, or therapeutic effect.

For example, a patent application for a new pharmaceutical compound may state that the compound is useful for treating a particular disease. Depending on the circumstances, experimental evidence may help establish that the compound actually provides the asserted therapeutic effect.

The USPTO recognizes that different types of evidence can be relevant to establishing an asserted utility. For therapeutic or pharmacological inventions, evidence such as in vitro testing, animal studies, or other biological data may help establish that the claimed therapeutic use is credible.

The amount of evidence needed depends on the circumstances. There is no universal requirement that a particular number of experiments or tests must be performed before filing.

For inventions involving biotechnology or pharmaceuticals, it can therefore be useful to consider the expected utility of the invention before filing and determine whether available data adequately supports that utility. Biotechnology patents may present particular challenges because biological activity can be difficult to predict from structure alone.

Supporting the Claimed Utility

Testing data can also be important when the patent claims a particular property or function.

For example, an application might claim a pharmaceutical compound that provides a particular therapeutic effect, a composition having improved stability, or a biological molecule having a particular level of activity.

The question is not simply whether one embodiment has been tested. The disclosure should provide a reasonable basis for concluding that the claimed invention has the asserted property.

This becomes particularly important when seeking broad claims.

Working Examples and Genus Claims

A patent application may describe a genus that encompasses many different compounds, proteins, sequences, or other embodiments. The inventor may have tested only a subset of those embodiments.

Those tested embodiments can serve as working examples demonstrating that particular members of the genus work. But the existence of a few working examples does not automatically establish that every embodiment within a broad genus will have the claimed property.

For example, an inventor may develop a new class of pharmaceutical compounds and test several compounds from that class. If the tested compounds all demonstrate the desired therapeutic activity, the results can provide evidence supporting the broader disclosure.

The usefulness of those examples depends in part on how representative they are of the claimed genus. A small number of examples may provide meaningful support when the technology is predictable and the examples adequately represent the claimed scope. A broader or more unpredictable genus may require more substantial disclosure and evidence.

Testing can also help establish a relationship between the structure of an invention and its claimed function. For example, if testing demonstrates that particular structural modifications consistently produce a desired biological effect, that data can support a reasonable structure-function relationship across a broader group of compounds.

This is one reason testing data can be particularly valuable in biotechnology and pharmaceutical patent applications.

Unexpected Results and Patentability

Testing data can also play an important role in establishing that an invention is not obvious.

An invention may appear similar to one or more prior art references while nevertheless producing an unexpected result. Comparative testing can provide evidence of that difference.

For example, testing may demonstrate that a new pharmaceutical compound has:

greater therapeutic efficacy;
substantially lower toxicity;
improved stability;
increased selectivity;
improved bioavailability; or
another advantage over compounds described in the prior art.

These results may help establish that the invention provides an unexpected advantage that would not have been reasonably expected from the prior art.

For example, suppose a new drug candidate is structurally similar to known compounds but testing demonstrates substantially lower toxicity while maintaining therapeutic activity. Comparative data showing that advantage may be useful in responding to an obviousness rejection.

The testing should generally be tied to the claimed invention and compared against an appropriate baseline or prior-art compound. The more closely the testing corresponds to the scope of the claims and the relevant prior art, the more useful the results may be.

This is particularly important when seeking to establish superiority. If an inventor believes an invention performs substantially better than existing technology, demonstrating that advantage with comparative testing can provide valuable evidence during patent prosecution. Patentability searches can also help identify the prior art against which those advantages should be evaluated.

What Testing Data Is Actually Needed?

There is no universal amount or type of testing data required for a patent application.

The appropriate testing depends on the invention, the technology, the claimed utility, and the scope of the claims.

For some inventions, little or no experimental testing may be necessary. An inventor may be able to adequately describe how to make and use the invention based on established principles and the information available in the field.

For other inventions, particularly those involving new biological or therapeutic effects, testing may be much more important.

When deciding whether additional testing would be useful, consider:

What utility is being claimed? Does the available evidence support the specific use being claimed?
How predictable is the technology? Results may be more difficult to predict in fields such as biotechnology and pharmacology.
How broad are the claims? A few examples may provide less support for a broad genus than for a narrowly defined group of embodiments.
Are the tested embodiments representative? Testing should provide meaningful information about the scope of the invention being claimed.
Are there unexpected advantages? If the invention appears similar to the prior art, comparative testing may help demonstrate an unexpected result.
Would additional testing materially strengthen the application? Additional experiments may be worthwhile when they could provide evidence supporting a valuable claim or an important distinction over the prior art.

Testing therefore should not be viewed simply as a prerequisite to filing. Instead, testing data should be considered part of the overall evidence supporting the patent application.

Should You Test an Invention Before Filing?

Not necessarily.

An inventor does not generally need to build a commercial product or completely test an invention before filing a patent application. Working examples are not categorically required, and a patent application may include prophetic examples describing experiments that are expected to produce particular results.

However, predicted results should not be presented as though they were actually obtained. Actual testing and predicted testing should be clearly distinguished in the application.

The more important question is whether the application provides sufficient information to support and enable the claims being pursued.

For an early-stage invention, it may therefore make sense to file before all testing is complete, particularly when preserving an early filing date is important. A provisional patent application can sometimes provide additional time to develop the invention and obtain additional data, although the provisional application still needs to adequately describe and support the invention.

Testing Data Should Support the Patent Strategy

Testing data is most valuable when it is considered alongside the claims being pursued.

For a pharmaceutical or biotechnology invention, data may help establish therapeutic utility, demonstrate that representative embodiments of a broader genus work, support a claimed property, or demonstrate an unexpected advantage over the prior art.

The goal is not simply to accumulate as much testing data as possible. The goal is to have the right evidence to support the invention and the scope of patent protection being sought.

When preparing a patent application, it is therefore worth considering not only what has already been tested, but also what the testing demonstrates, which claims the data supports, and whether additional testing could materially strengthen the patent position.

Schedule A Consultation

Tagged Biotech, IP